{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T18:18:13Z","timestamp":1787509093936,"version":"build-2736575974"},"reference-count":136,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ejmech.2021.114062","type":"journal-article","created":{"date-parts":[[2021,12,20]],"date-time":"2021-12-20T20:20:34Z","timestamp":1640031634000},"page":"114062","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"special_numbering":"C","title":["DYRK1A inhibitors for disease therapy: Current status and perspectives"],"prefix":"10.1016","volume":"229","author":[{"given":"Tong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8618-9200","authenticated-orcid":false,"given":"Jifa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.114062_bib1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1096\/fj.10-165837","article-title":"DYRK family of protein kinases: evolutionary relationships, biochemical properties, and functional roles","volume":"25","author":"Aranda","year":"2011","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2021.114062_bib2","doi-asserted-by":"crossref","first-page":"9098","DOI":"10.3390\/ijms22169098","article-title":"Master regulators in neurodegenerative pathways","volume":"22","author":"Demuro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.114062_bib3","doi-asserted-by":"crossref","first-page":"17876","DOI":"10.1038\/s41598-019-54188-w","article-title":"Construction of miRNA-target networks using microRNA profiles of CVB3-infected HeLa cells","volume":"9","author":"Yao","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.114062_bib4","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.4161\/cc.29104","article-title":"The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation","volume":"13","author":"Soppa","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2021.114062_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1742-4658.2010.07954.x","article-title":"MNB\/DYRK1A as a multiple regulator of neuronal development","volume":"278","author":"Tejedor","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2021.114062_bib6","doi-asserted-by":"crossref","first-page":"9814","DOI":"10.1021\/acs.jmedchem.6b01086","article-title":"Probing the ATP-binding pocket of protein kinase DYRK1A with benzothiazole fragment molecules","volume":"59","author":"Rothweiler","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib7","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.bmcl.2013.10.055","article-title":"Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors","volume":"23","author":"Anderson","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114062_bib8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.str.2013.03.012","article-title":"Structures of Down syndrome kinases, DYRKs, reveal mechanisms of kinase activation and substrate recognition","volume":"21","author":"Soundararajan","year":"2013","journal-title":"Structure"},{"key":"10.1016\/j.ejmech.2021.114062_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gene.2012.07.083","article-title":"Function of alternative splicing","volume":"514","author":"Kelemen","year":"2013","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2021.114062_bib10","doi-asserted-by":"crossref","first-page":"13223","DOI":"10.1074\/jbc.M110.102574","article-title":"DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1","volume":"285","author":"Guo","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib11","article-title":"The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells","volume":"22","author":"Khor","year":"2015","journal-title":"Elife"},{"key":"10.1016\/j.ejmech.2021.114062_bib12","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/j.celrep.2018.04.008","article-title":"DYRK1A kinase positively regulates angiogenic responses in endothelial cells","volume":"23","author":"Rozen","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2021.114062_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3390\/brainsci8100187","article-title":"DYRK1A protein, A promising therapeutic target to improve cognitive deficits in down syndrome","volume":"8","author":"Feki","year":"2018","journal-title":"Brain Sci."},{"key":"10.1016\/j.ejmech.2021.114062_bib14","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/cn300094k","article-title":"Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?","volume":"3","author":"Smith","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2021.114062_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.pharmthera.2015.03.004","article-title":"DYRK1A in neurodegeneration and cancer: molecular basis and clinical implications","volume":"151","author":"Abbassi","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2021.114062_bib16","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1021\/acs.jmedchem.0c02050","article-title":"DYRK1A inhibitors as potential therapeutics for beta-cell regeneration for diabetes","volume":"64","author":"Kumar","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","article-title":"The role of DYRK1A in neurodegenerative diseases","volume":"278","author":"Wegiel","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2021.114062_bib18","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/alz.12068","article-title":"2020 Alzheimer's disease facts and figures","volume":"16","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ejmech.2021.114062_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.phrs.2017.12.009","article-title":"Alzheimer's disease and gut microbiota modifications: the long way between preclinical studies and clinical evidence","volume":"129","author":"Mancuso","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2021.114062_bib20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/mnfr.201500781","article-title":"Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model","volume":"60","author":"Abeysekera","year":"2016","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejmech.2021.114062_bib21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.abb.2010.12.024","article-title":"Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A)","volume":"507","author":"Adayev","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2021.114062_bib22","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3390\/md15100316","article-title":"Marine-derived 2-aminoimidazolone alkaloids. Leucettamine B-related polyandrocarpamines inhibit mammalian and Protozoan DYRK & CLK kinases","volume":"15","author":"Loaec","year":"2017","journal-title":"Mar. Drugs"},{"key":"10.1016\/j.ejmech.2021.114062_bib23","doi-asserted-by":"crossref","first-page":"9569","DOI":"10.1021\/jm401049v","article-title":"Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity","volume":"56","author":"Gourdain","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib24","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1016\/j.bmc.2015.06.018","article-title":"Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis","volume":"23","author":"Masaki","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib25","doi-asserted-by":"crossref","first-page":"10268","DOI":"10.1073\/pnas.1704143114","article-title":"Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice","volume":"114","author":"Nakano-Kobayashi","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.114062_bib26","doi-asserted-by":"crossref","first-page":"11391","DOI":"10.1038\/ncomms11391","article-title":"Selective inhibition of the kinase DYRK1A by targeting its folding process","volume":"7","author":"Kii","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.114062_bib27","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1080\/13543776.2017.1360285","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature","volume":"27","author":"Nguyen","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.ejmech.2021.114062_bib28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mnfr.201300325","article-title":"Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans","volume":"58","author":"De la Torre","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejmech.2021.114062_bib29","first-page":"5615647","article-title":"Green tea extracts epigallocatechin-3-gallate for different treatments","author":"Chu","year":"2017","journal-title":"Biomed. Res. Int., 2017"},{"key":"10.1016\/j.ejmech.2021.114062_bib30","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3390\/molecules25143146","article-title":"Potential therapeutic targets of epigallocatechin gallate (EGCG), the most abundant catechin in green tea, and its role in the therapy of various types of cancer","volume":"25","author":"Almatroodi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.114062_bib31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.bbadis.2016.03.003","article-title":"The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model","volume":"1862","author":"Valenti","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2021.114062_bib32","doi-asserted-by":"crossref","first-page":"113554","DOI":"10.1016\/j.ejmech.2021.113554","article-title":"Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3beta\/DYRK1A dual inhibitors for the treatment of Alzheimer's disease","volume":"222","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib33","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1021\/acs.jmedchem.9b01379","article-title":"Synthesis and biological validation of a harmine-based, central nervous system (CNS)-Avoidant, selective, human beta-cell regenerative dual-specificity tyrosine phosphorylation-regulated kinase A (DYRK1A) inhibitor","volume":"63","author":"Kumar","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib34","doi-asserted-by":"crossref","first-page":"11709","DOI":"10.1021\/acs.jmedchem.1c01115","article-title":"Discovery and characterization of selective and ligand-efficient DYRK inhibitors","volume":"64","author":"Henderson","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib35","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.ejmech.2018.07.050","article-title":"Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: benzamide and benzylamide derivatives","volume":"157","author":"Darwish","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib36","doi-asserted-by":"crossref","first-page":"6745","DOI":"10.1021\/acs.jmedchem.1c00023","article-title":"Structure-guided discovery of potent and selective DYRK1A inhibitors","volume":"64","author":"Weber","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib37","doi-asserted-by":"crossref","first-page":"8971","DOI":"10.1021\/acs.jmedchem.1c00024","article-title":"Fragment-derived selective inhibitors of dual-specificity kinases DYRK1A and DYRK1B","volume":"64","author":"Lee Walmsley","year":"2021","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib38","doi-asserted-by":"crossref","first-page":"e494","DOI":"10.1002\/ctm2.494","article-title":"A\u00a0natural DYRK1A inhibitor as a potential stimulator for beta-cell proliferation in diabetes","volume":"11","author":"Zheng","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.ejmech.2021.114062_bib39","doi-asserted-by":"crossref","first-page":"153695","DOI":"10.1016\/j.phymed.2021.153695","article-title":"Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes","volume":"92","author":"Choi","year":"2021","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ejmech.2021.114062_bib40","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1021\/acsmedchemlett.0c00279","article-title":"Mining public domain data to develop selective DYRK1A inhibitors","volume":"11","author":"Henderson","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.114062_bib41","doi-asserted-by":"crossref","first-page":"9791","DOI":"10.1021\/acs.jmedchem.8b00185","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors as potential therapeutics","volume":"61","author":"Jarhad","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib42","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jnc.13018","article-title":"A\u00a0novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in\u00a0vitro","volume":"133","author":"Coutadeur","year":"2015","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2021.114062_bib43","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1471-4159.2010.06769.x","article-title":"Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease","volume":"115","author":"Ryu","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2021.114062_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.neulet.2016.04.014","article-title":"The GBA, DYRK1A and MS4A6A polymorphisms influence the age at onset of Chinese Parkinson patients","volume":"621","author":"Fan","year":"2016","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2021.114062_bib45","first-page":"1315","article-title":"DYRK1A kinase inhibitors with emphasis on cancer","volume":"12","author":"Ionescu","year":"2012","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib46","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1111\/jcmm.14609","article-title":"DYRK1A inhibition suppresses STAT3\/EGFR\/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291","volume":"23","author":"Li","year":"2019","journal-title":"J.\u00a0Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2021.114062_bib47","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1158\/0008-5472.CAN-16-1571","article-title":"Ablation of miR-10b suppresses oncogene-induced mammary tumorigenesis and metastasis and reactivates tumor-suppressive pathways","volume":"76","author":"Kim","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.114062_bib48","doi-asserted-by":"crossref","first-page":"36132","DOI":"10.1038\/srep36132","article-title":"A\u00a0dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma","volume":"6","author":"Radhakrishnan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.114062_bib49","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00018-020-03626-4","article-title":"DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis","volume":"78","author":"Laham","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2021.114062_bib50","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1038\/ncomms9372","article-title":"Inhibition of DYRK1A and GSK3B induces human beta-cell proliferation","volume":"6","author":"Shen","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.114062_bib51","doi-asserted-by":"crossref","first-page":"104268","DOI":"10.1016\/j.yexmp.2019.104268","article-title":"Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome","volume":"110","author":"Quinones-Lombrana","year":"2019","journal-title":"Exp. Mol. Pathol."},{"key":"10.1016\/j.ejmech.2021.114062_bib52","doi-asserted-by":"crossref","first-page":"134541","DOI":"10.1016\/j.neulet.2019.134541","article-title":"microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing","volume":"714","author":"Chaves","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2021.114062_bib53","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.nbd.2017.12.002","article-title":"Cerebellar alterations in a model of Down syndrome: the role of the Dyrk1A gene","volume":"110","author":"Garcia-Cerro","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2021.114062_bib54","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1038\/s41598-019-43820-4","article-title":"Downregulated Wnt\/beta-catenin signalling in the Down syndrome hippocampus","volume":"9","author":"Granno","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.114062_bib55","doi-asserted-by":"crossref","first-page":"5899","DOI":"10.1128\/MCB.00394-08","article-title":"Sprouty2-mediated inhibition of fibroblast growth factor signaling is modulated by the protein kinase DYRK1A","volume":"28","author":"Aranda","year":"2008","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.114062_bib56","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbrc.2017.07.107","article-title":"Identification of a DYRK1A-mediated phosphorylation site within the nuclear localization sequence of the hedgehog transcription factor GLI1","volume":"491","author":"Ehe","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2021.114062_bib57","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.15252\/embr.201540374","article-title":"DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model","volume":"16","author":"Kurabayashi","year":"2015","journal-title":"EMBO Rep."},{"key":"10.1016\/j.ejmech.2021.114062_bib58","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5607\/en.2011.20.1.35","article-title":"Dyrk1A positively stimulates ASK1-JNK signaling pathway during apoptotic cell death","volume":"20","author":"Choi","year":"2011","journal-title":"Exp. Neurobiol."},{"key":"10.1016\/j.ejmech.2021.114062_bib59","doi-asserted-by":"crossref","first-page":"112656","DOI":"10.1016\/j.yexcr.2021.112656","article-title":"DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral\/oropharyngeal squamous cell carcinoma","volume":"405","author":"Martin","year":"2021","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2021.114062_bib60","doi-asserted-by":"crossref","first-page":"49409","DOI":"10.18632\/oncotarget.17219","article-title":"LncRNA OIP5-AS1\/cyrano suppresses GAK expression to control mitosis","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.114062_bib61","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejcb.2018.04.005","article-title":"LncRNA OIP5-AS1 regulates radioresistance by targeting DYRK1A through miR-369-3p in colorectal cancer cells","volume":"97","author":"Zou","year":"2018","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.ejmech.2021.114062_bib62","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.3390\/ijms22084011","article-title":"DYRK1A negatively regulates CDK5-SOX2 pathway and self-renewal of glioblastoma stem cells","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2021.114062_bib63","doi-asserted-by":"crossref","first-page":"144960","DOI":"10.1016\/j.gene.2020.144960","article-title":"The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma","volume":"758","author":"Bai","year":"2020","journal-title":"Gene"},{"key":"10.1016\/j.ejmech.2021.114062_bib64","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1136\/gutjnl-2018-316128","article-title":"DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth","volume":"68","author":"Luna","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.ejmech.2021.114062_bib65","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/mp.2016.253","article-title":"Autism-associated Dyrk1a truncation mutants impair neuronal dendritic and spine growth and interfere with postnatal cortical development","volume":"23","author":"Dang","year":"2018","journal-title":"Mol. Psychiatr."},{"key":"10.1016\/j.ejmech.2021.114062_bib66","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.nbd.2017.12.003","article-title":"DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures","volume":"110","author":"Raveau","year":"2018","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2021.114062_bib67","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.3233\/JAD-190475","article-title":"Abnormalities of DYRK1A-cytoskeleton complexes in the blood cells as potential biomarkers of Alzheimer's disease","volume":"72","author":"Dowjat","year":"2019","journal-title":"J.\u00a0Alzheimers. Dis."},{"key":"10.1016\/j.ejmech.2021.114062_bib68","doi-asserted-by":"crossref","first-page":"20164","DOI":"10.1074\/jbc.RA119.010809","article-title":"Dual-specificity tyrosine phosphorylation-regulated kinase 1A ameliorates insulin resistance in neurons by up-regulating IRS-1 expression","volume":"294","author":"Tian","year":"2019","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib69","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.tice.2018.10.002","article-title":"Dyrk1A promotes the proliferation, migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis via down-regulating Spry2 and activating the ERK MAPK pathway","volume":"55","author":"Guo","year":"2018","journal-title":"Tissue Cell"},{"key":"10.1016\/j.ejmech.2021.114062_bib70","doi-asserted-by":"crossref","DOI":"10.1172\/JCI135937","article-title":"DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3","volume":"131","author":"Bhansali","year":"2021","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2021.114062_bib71","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1021\/jm049060w","article-title":"Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships","volume":"48","author":"Marco","year":"2005","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib72","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejmech.2012.01.040","article-title":"Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class","volume":"49","author":"Neagoie","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib73","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/jm501994d","article-title":"10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A","volume":"58","author":"Falke","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib74","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2014.04.055","article-title":"Synthesis and optimization of an original V-shaped collection of 4-7-disubstituted pyrido[3,2-d]pyrimidines as CDK5 and DYRK1A inhibitors","volume":"80","author":"Dehbi","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib75","first-page":"655","article-title":"Cyclin-dependent kinase 5 is associated with risk for Alzheimer's disease in a Dutch population-based study","volume":"255","author":"Arias-Vasquez","year":"2008","journal-title":"J.\u00a0Neurol."},{"key":"10.1016\/j.ejmech.2021.114062_bib76","doi-asserted-by":"crossref","first-page":"34850","DOI":"10.1074\/jbc.M707358200","article-title":"DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease","volume":"282","author":"Ryoo","year":"2007","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib77","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1021\/jm200464w","article-title":"Synthesis, protein kinase inhibitory potencies, and in\u00a0vitro antiproliferative activities of meridianin derivatives","volume":"54","author":"Giraud","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib78","doi-asserted-by":"crossref","first-page":"539","DOI":"10.2174\/1389450115666140226112321","article-title":"Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease","volume":"15","author":"Jain","year":"2014","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2021.114062_bib79","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1007\/s12035-015-9369-x","article-title":"The role of Cdk5 in Alzheimer's disease","volume":"53","author":"Liu","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejmech.2021.114062_bib80","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.3390\/cells9051110","article-title":"Targeting GSK3 and associated signaling pathways involved in cancer","volume":"9","author":"Duda","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2021.114062_bib81","doi-asserted-by":"crossref","first-page":"118664","DOI":"10.1016\/j.bbamcr.2020.118664","article-title":"Glycogen synthase kinase-3 signaling in Alzheimer's disease","volume":"1867","author":"Lauretti","year":"2020","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10.1016\/j.ejmech.2021.114062_bib82","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1021\/jm200274d","article-title":"Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing","volume":"54","author":"Debdab","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib83","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ejmech.2016.02.017","article-title":"Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2","volume":"112","author":"Mariano","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib84","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.ejmech.2016.09.064","article-title":"Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor","volume":"125","author":"Bendjeddou","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib85","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1016\/j.ejmech.2011.08.048","article-title":"Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents","volume":"46","author":"Kassis","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib86","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1021\/acs.jmedchem.6b01840","article-title":"Structural optimization and pharmacological evaluation of inhibitors targeting dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) and CDC-like kinases (CLK) in glioblastoma","volume":"60","author":"Zhou","year":"2017","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib87","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejmech.2016.04.004","article-title":"Discovery of pyrido[3,4-g]quinazoline derivatives as CMGC family protein kinase inhibitors: design, synthesis, inhibitory potency and X-ray co-crystal structure","volume":"118","author":"Esvan","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib88","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/cmdc.201600539","article-title":"Structure-based design and synthesis of harmine derivatives with different selectivity profiles in kinase versus monoamine oxidase inhibition","volume":"12","author":"B\u00e1lint","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.114062_bib89","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncomms1090","article-title":"Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A","volume":"1","author":"Ogawa","year":"2010","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2021.114062_bib90","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.ejmech.2018.08.007","article-title":"Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic beta-cell proliferation activity","volume":"157","author":"Kumar","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib91","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1002\/cmdc.202000183","article-title":"A\u00a0dual inhibitor of DYRK1A and GSK3beta for beta-cell proliferation: aminopyrazine derivative GNF4877","volume":"15","author":"Liu","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.114062_bib92","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.1021\/acs.jmedchem.9b01624","article-title":"Selective DYRK1A inhibitor for the treatment of type 1 diabetes: discovery of 6-azaindole derivative GNF2133","volume":"63","author":"Liu","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib93","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.2147\/OTT.S205097","article-title":"Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment","volume":"12","author":"Wu","year":"2019","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2021.114062_bib94","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.3892\/or.2017.5952","article-title":"Harmine suppresses the proliferation and migration of human ovarian cancer cells through inhibiting ERK\/CREB pathway","volume":"38","author":"Gao","year":"2017","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2021.114062_bib95","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3389\/fphar.2018.00346","article-title":"Analogous beta-carboline alkaloids harmaline and harmine ameliorate scopolamine-induced cognition dysfunction by attenuating acetylcholinesterase activity, oxidative stress, and inflammation in mice","volume":"9","author":"Li","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.114062_bib96","doi-asserted-by":"crossref","first-page":"7985","DOI":"10.3892\/mmr.2015.4437","article-title":"Treatment with harmine ameliorates functional impairment and neuronal death following traumatic brain injury","volume":"12","author":"Zhong","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2021.114062_bib97","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1021\/acs.jafc.9b07694","article-title":"Synthesis of four optical isomers of antiviral agent NK0209 and determination of their configurations and activities against a plant virus","volume":"68","author":"Wang","year":"2020","journal-title":"J.\u00a0Agric. Food Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib98","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s12272-020-01283-6","article-title":"Pharmacological effects of harmine and its derivatives: a review","volume":"43","author":"Zhang","year":"2020","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.ejmech.2021.114062_bib99","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nm.3820","article-title":"A\u00a0high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication","volume":"21","author":"Wang","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2021.114062_bib100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019264","article-title":"beta-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites","volume":"6","author":"Frost","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.114062_bib101","doi-asserted-by":"crossref","first-page":"7687","DOI":"10.1021\/acs.jmedchem.8b00658","article-title":"Development of kinase-selective, harmine-based DYRK1A inhibitors that induce pancreatic human beta-cell proliferation","volume":"61","author":"Kumar","year":"2018","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib102","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0773.1987.tb01711.x","article-title":"Tremorigenic effect and inhibition of tryptamine and serotonin receptor binding by beta-carbolines","volume":"60","author":"Airaksinen","year":"1987","journal-title":"Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2021.114062_bib103","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.pnpbp.2012.06.001","article-title":"Developments in harmine pharmacology--implications for ayahuasca use and drug-dependence treatment","volume":"39","author":"Brierley","year":"2012","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejmech.2021.114062_bib104","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.cmet.2018.12.005","article-title":"Combined inhibition of DYRK1A, SMAD, and trithorax pathways synergizes to induce robust replication in adult human beta cells","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2021.114062_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029252","article-title":"Hydroxybenzothiazoles as new nonsteroidal inhibitors of 17\u03b2-hydroxysteroid dehydrogenase type 1 (17\u03b2-HSD1)","volume":"7","author":"Spadaro","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.114062_bib106","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1039\/C8MD00142A","article-title":"Design and synthesis of conformationally constraint Dyrk1A inhibitors by creating an intramolecular H-bond involving a benzothiazole core","volume":"9","author":"Salah","year":"2018","journal-title":"Med. chem. comm."},{"key":"10.1016\/j.ejmech.2021.114062_bib107","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4103\/1673-5374.245463","article-title":"Multitarget therapeutic strategies for Alzheimer's disease","volume":"14","author":"Ibrahim","year":"2019","journal-title":"Neural. Regen. Res."},{"key":"10.1016\/j.ejmech.2021.114062_bib108","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejmech.2019.05.020","article-title":"Multi-target design strategies for the improved treatment of Alzheimer's disease","volume":"176","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib109","doi-asserted-by":"crossref","first-page":"113911","DOI":"10.1016\/j.ejmech.2021.113911","article-title":"Discovery of novel 6-hydroxybenzothiazole urea derivatives as dual Dyrk1A\/alpha-synuclein aggregation inhibitors with neuroprotective effects","volume":"227","author":"AlNajjar","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib110","article-title":"Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome","volume":"12","author":"Zhao","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.114062_bib111","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0087851","article-title":"Design and synthesis of a library of lead-like 2,4-bisheterocyclic substituted thiophenes as selective Dyrk\/Clk inhibitors","volume":"9","author":"Schmitt","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.114062_bib112","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.ejmech.2018.08.097","article-title":"Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: identification of the cyclopropylamide moiety as a key modification","volume":"158","author":"Darwish","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib113","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/s41598-018-20984-z","article-title":"DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives","volume":"8","author":"Neumann","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.114062_bib114","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1055\/s-2004-818964","article-title":"Aristolactam BII of Saururus chinensis attenuates glutamate-induced neurotoxicity in rat cortical cultures probably by inhibiting nitric oxide production","volume":"70","author":"Kim","year":"2004","journal-title":"Planta Med."},{"key":"10.1016\/j.ejmech.2021.114062_bib115","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/14786419.2012.688044","article-title":"Antioxidant and antimicrobial activities of aporphinoids and other alkaloids from the bark of Annona salzmannii A. DC. (Annonaceae)","volume":"27","author":"Costa","year":"2013","journal-title":"Nat. Prod. Res."},{"key":"10.1016\/j.ejmech.2021.114062_bib116","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.brainres.2011.03.052","article-title":"Association analysis of GSK3B and MAPT polymorphisms with Alzheimer's disease in Han Chinese","volume":"1391","author":"Zhang","year":"2011","journal-title":"Brain Res."},{"key":"10.1016\/j.ejmech.2021.114062_bib117","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1016\/j.bmcl.2016.07.032","article-title":"Synthesis and preliminary in\u00a0vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives","volume":"26","author":"Zeinyeh","year":"2016","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.114062_bib118","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ejmech.2019.01.052","article-title":"New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis","volume":"166","author":"Tazarki","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.114062_bib119","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1038\/onc.2010.264","article-title":"Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty\/c-Met upregulation in human colonic adenocarcinomas","volume":"29","author":"Holgren","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2021.114062_bib120","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/hep.23681","article-title":"Synergistic role of Sprouty2 inactivation and c-Met up-regulation in mouse and human hepatocarcinogenesis","volume":"52","author":"Lee","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2021.114062_bib121","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3390\/cancers13010115","article-title":"Perspectives on the role of isoliquiritigenin in cancer","volume":"13","author":"Wang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2021.114062_bib122","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.phrs.2019.04.025","article-title":"Natural products in licorice for the therapy of liver diseases: progress and future opportunities","volume":"144","author":"Li","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2021.114062_bib123","doi-asserted-by":"crossref","first-page":"108913","DOI":"10.1016\/j.cbi.2019.108913","article-title":"Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A","volume":"316","author":"Zhao","year":"2020","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2021.114062_bib124","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/molecules23020064","article-title":"Indole-3-Carbonitriles as DYRK1A inhibitors by fragment-based drug design","volume":"23","author":"Meine","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.114062_bib125","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.3390\/molecules24224090","article-title":"[b]-Annulated halogen-substituted indoles as potential DYRK1A inhibitors","volume":"24","author":"Lechner","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.114062_bib126","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1021\/acs.orglett.6b01552","article-title":"Pd-catalyzed and copper assisted regioselective sequential C2 and C7 arylation of thiazolo[5,4-f]quinazolin-9(8H)-one with aryl halides","volume":"18","author":"Harari","year":"2016","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2021.114062_bib127","doi-asserted-by":"crossref","DOI":"10.3390\/molecules21050578","article-title":"Synthesis of thiazolo[5,4-f]quinazolin-9(8H)-ones as multi-target directed ligands of ser\/thr kinases","volume":"21","author":"Hedou","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.114062_bib128","doi-asserted-by":"crossref","first-page":"15546","DOI":"10.3390\/molecules191015546","article-title":"Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I","volume":"19","author":"Foucourt","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.114062_bib129","doi-asserted-by":"crossref","first-page":"15411","DOI":"10.3390\/molecules191015411","article-title":"Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part II","volume":"19","author":"Foucourt","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.114062_bib130","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3390\/molecules23092181","article-title":"Development of kinase inhibitors via metal-catalyzed C(-)H arylation of 8-Alkyl-thiazolo[5,4-f]-quinazolin-9-ones designed by fragment-growing studies","volume":"23","author":"Couly","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.114062_bib131","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw9996","article-title":"GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human \u03b2 cell regeneration","volume":"12","author":"Ackeifi","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2021.114062_bib132","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.mad.2016.04.012","article-title":"Chemical screening identifies the beta-Carboline alkaloid harmine to be synergistically lethal with doxorubicin","volume":"161","author":"Atteya","year":"2017","journal-title":"Mech. Ageing Dev."},{"key":"10.1016\/j.ejmech.2021.114062_bib133","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cmet.2019.09.014","article-title":"A\u00a0novel allosteric inhibitor of phosphoglycerate mutase 1 suppresses growth and metastasis of non-small-cell lung cancer","volume":"30","author":"Huang","year":"2019","journal-title":"Cell Metabol."},{"key":"10.1016\/j.ejmech.2021.114062_bib134","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2159-8290.CD-18-0903","article-title":"Single and dual targeting of mutant EGFR with an allosteric inhibitor","volume":"9","author":"To","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2021.114062_bib135","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2021.114062_bib136","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem. Funct."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421009119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:34:49Z","timestamp":1759329289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421009119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":136,"alternative-id":["S0223523421009119"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114062","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DYRK1A inhibitors for disease therapy: Current status and perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.114062","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114062"}}